Do thiazides worsen metabolic syndrome and renal disease? The pivotal roles for hyperuricemia and hypokalemia

Current Opinion in Nephrology and Hypertension

Volumn 17, Issue 5, 2008, Pages 470-476

  Reungjui, Sirirat ^a   Pratipanawatr, Thongchai ^a   Johnson, Richard J ^b   Nakagawa, Takahiko ^b  

^a KHON KAEN UNIVERSITY   (Thailand)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Endothelial dysfunction; Hyperuricemia; Hypokalemia; Metabolic syndrome; Renal injury; Thiazides

Indexed keywords

ALLOPURINOL; AMLODIPINE; BENDROFLUMETHIAZIDE; CHLORTALIDONE; DOXAZOSIN; HYDROCHLOROTHIAZIDE; LISINOPRIL; METOLAZONE; POTASSIUM; QUINETHAZONE; THIAZIDE DIURETIC AGENT; URIC ACID;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CALCIUM STONE; CLINICAL FEATURE; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; DRUG SUBSTITUTION; FRACTURE; HEART FAILURE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; HYPOKALEMIA; HYPOURICEMIA; INSULIN RESISTANCE; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY INJURY; LOW DRUG DOSE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOPOROSIS; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION; STROKE; URIC ACID BLOOD LEVEL; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; KIDNEY; METABOLISM; PATHOPHYSIOLOGY;

HUMANS; HYPERTENSION; HYPERURICEMIA; HYPOKALEMIA; KIDNEY; KIDNEY DISEASES; METABOLIC SYNDROME X; SODIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 58149346039     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e328305b9a5     Document Type: Review

References (82)

1. Hollander W, Wilkins RW. Chlorothiazide: a new type of drug for the treatment of arterial hypertension. BMQ 1957; 8:69-75.
2. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program(SHEP). JAMA 1991; 265:3255-3264.
3. Patel AB, Kostis JB, Wilson AC, et al. Long-term fatal outcomes in subjects with stroke or transient ischemic attack: fourteen-year follow-up of the systolic hypertension in the elderly program. Stroke 2008; 39:1084-1089.
4. Mortality after 101/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation 1990; 82:1616-1628.
5. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systemic review and meta-analysis. JAMA 1997; 277:739-745.
6. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997.
7. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention. Detection, evaluation, and treatment of high blood pressure. The JNC 7 Report. JAMA 2003; 289:2560-2572.
8. Campese VM. Diuretics are preferred over angiotensin II-converting enzyme inhibitors for initial therapy of uncomplicated hypertension. Am J Kidney Dis 2007; 50:197-202.
9. Hebert LA, Rovin BH, Hebert CJ. The design of ALLHAT may have biased the study's outcome in favor of the diuretic cohort. Nat Clin Pract Nephrol 2007; 3:60-61.
10. Rovin BH, Hebert LA. Thiazide diuretic monotherapy for hypertension: diuretic's dark side just got darker. Kidney Int 2007; 72:1423-1426.
11. Houston MC. ALLHAT debate: diuretics are not preferred, first-line initial therapy for hypertension. Arch Intern Med 2004; 164:570-571.
12. Morganti A. Should a diuretic always be the first choice in patients with essential hypertension? The case for no. J Am Soc Nephrol 2005; 16 (Suppl 1):S70-S73.
13. Grimm R. Diuretics are preferred over angiotensin II-converting enzyme inhibitors for initial therapy of uncomplicated hypertension. Am J Kidney Dis 2007; 50:188-196.
14. Hughes AD. How do thiazide and thiazide-like diuretics lower blood pressure? J Renin Angiotensin Aldosterone Syst 2004; 5:155-160.
15. Zhu Z, Zhu S, Liu D, et al. Thiazide-like diuretics attenuate agonist-induced vasoconstriction by calcium desensitization linked to Rho kinase. Hypertension 2005; 45:233-239.
16. Puscas I, Coltau M, Baican M, et al. Vasodilatory effect of diuretics is dependent on inhibition of vascular smooth muscle carbonic anhydrase by a direct mechanism of action. Drugs Exp Clin Res 1999; 25:271 -279.
17. Chen TM, Chiou WL. Large differences in the biological half-life and volume of distribution of hydrochlorothiazide in normal subjects from eleven studies. Correlation with their last blood sampling times. Int J Clin Pharmacol Ther Toxicol 1992; 30:34-37.
18. Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006; 47:352-358.
19. Khosla N, Elliott WJ, Bakris GL. Are chlorthalidone and hydrochorothiazide equivalent blood pressure-lowering medications? [Commentary]. J Clin Hypertens (Greenwich) 2005; 7:354-356.
20. Sica DA. Chlorthalidone: has it always been the best thiazide-type diuretic? Hypertension 2006; 47:321-322.
21. Choi K, Chua D, Elliott WJ. Chlorthalidone vs. other low-dose diuretics [letter]. JAMA 2004; 292:1816-1817.
22. Elliott WJ. Systemic hypertension. Curr Probl Cardiol 2007; 32:201 -259.
23. Freis ED, Reda DJ, Materson BJ. Volume (weight) loss and blood pressure response following thiazide diuretics. Hypertension 1988; 12:244-250.
24. Chapman AB, Schwartz GL, Boerwinkle E, Turner ST. Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension. Kidney Int 2002; 61:1047-1055.
25. Arrabal-Martin M, Fernandez-Rodriguez A, Arrabal-Polo MA, et al. Extracorporeal renal lithotripsy: evolution of residual lithiasis treated with thiazides. Urology 2006; 68:956-959.
26. Bolland MJ, Ames RW, Horne AM, et al. The effect of treatment with a thiazide diuretic for 4 years on bone density in normal postmenopausal women. Osteoporos Int 2007; 18:479-486.
27. Feskanich D, Willett WC, Stampfer MJ, Colditz GA. A prospective study of thiazide use and fractures in women. Osteoporos Int 1997; 7:79-84.
28. Schoofs MW, van der Klift M, Hofman A, et al. Thiazide diuretics and the risk for hip fracture. Ann Intern Med 2003; 139:476-482.
29. Dvorak MM, De Joussineau C, Carter DH, et al. Thiazide diuretics directly induce osteoblast differentiation and mineralized nodule formation by interacting with a sodium chloride co-transporter in bone. J Am Soc Nephrol 2007; 18:2509-2516.
30. Rahman M, Pressel S, Davis BR, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005; 165:936-946.
31. Wright JT Jr, Harris-Haywood S, Pressel S, et al. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2008; 168:207-217.
32. Salvetti A, Ghiadoni L. Thiazide diuretics in the treatment of hypertension: an update. J Am Soc Nephrol 2006; 17 (4 Suppl 2):S25-S29.
33. Lindholm LH, Persson M, Alaupovic P, et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003; 21:1563-1574.
34. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43:963-969.
35. Black HR, Davis B, Barzilay J, et al. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care 2008; 31:353-360.
36. Fogari R, Derosa G, Zoppi A, et al. Effect of delapril/ manidipinevsolmesartan/ hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients. Intern Med 2008; 47:361 -366.
37. Fonseca FA, Ihara SS, Izar MC, et al. Hydrochlorothiazide abolishes the antiatherosclerotic effect of quinapril. Clin Exp Pharmacol Physiol 2003; 30:779-785.
38. Kasjfoglu T, Yalcin AU. The effects of thiazide and thiazide-potassium sparing diuretics on fibrinolytic system parameters. Anadolu Kardiyol Derg 2006; 6:143-147.
39. Mugellini A, Preti P, Zoppi A, et al. Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus. J Hum Hypertens 2004; 18:687-691.
40. Brown NJ, Kumar S, Painter CA, Vaughan DE. ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time. Hypertension 2002; 40:859-865.
41. Lottermoser K, Hertfelder HJ, Vetter H, Dusing R. Fibrinolytic function in diuretic-induced volume depletion. Am J Hypertens 2000; 13:359-363.
42. Dierkes J, Luley C, Westphal S. Effect of lipid-lowering and antihypertensive drugs on plasma homocysteine levels. Vasc Health Risk Manag 2007; 3:99-108.
43. Westphal S, Rading A, Luley C, Dierkes J. Antihypertensive treatment and homocysteine concentrations. Metabolism 2003; 52:261-263.
44. Grobbee DE, Hoes AW. Nonpotassium-sparing diuretics and risk of sudden cardiac death. J Hypertens 1995; 13:1539-1545.
45. Siscovick DS, Raghunathan TE, Psaty BM, et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994; 330:1852-1857.
46. Cohen HW, Madhavan S, Alderman MH. High and low serum potassium associated with cardiovascular events in diuretic-treated patients. J Hypertens 2001; 19:1315-1323.
47. Franse LV, Pahor M, Di Bari M, et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000; 18:1149-1154.
48. Kaplan NM, Carnegie A, Raskin P, et al. Potassium supplementation in hypertensive patients with diuretic-induced hypokalemia. N Engl J Med 1985; 312:746-749.
49. Zillich AJ, Garg J, Basu S, et al. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 2006; 48:219-224.
50. Reyes AJ. Diuretics in the therapy of hypertension. J Hum Hypertens 2002; 16:S78-S83.
51. Carlsen JE, Køber L, Torp-Pedersen C, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ 1990; 300:975-978.
52. Girvin B, Johnston GD. A randomized comparison of a conventional dose, a low dose and alternate-day dosing of bendrofluazide in hypertensive patients. J Hypertens 1998; 16:1049-1054.
53. Scholze J, Breitstadt A, Cairns V, et al. Short report: ramipril and hydrochlorothiazide combination therapy in hypertension: a clinical trial of factorial design. The East Germany Collaborative Trial Group. J Hypertens 1993; 11:217-221.
54. Alderman MH, Cohen H, Madhavan S, Kivlighn S. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 1999; 34:144-150.
55. Amery A, Birkenhager W, Brixko P, et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on high blood pressure in the elderly (EWPHE). Postgrad Med J 1986; 62:919-924.
56. Andersson OK, Gudbrandsson T, Jamerson K. Metabolic adverse effects of thiazide diuretics: the importance of normokalaemia. J Intern Med Suppl 1991; 735:89-96.
57. Helderman JH, Elahi D, Andersen DK, et al. Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium. Diabetes 1983; 32:106-111.
58. NorbiatoG, Bevilacqua M, Meroni R, et al. Effects of potassium supplementation on insulin binding and insulin action in human obesity: protein-modified fast and refeeding. Eur J Clin Invest 1984; 14:414-419.
59. Roy D, Perreault M, Marette A. Insulin stimulation of glucose uptake in skelet al. muscles and adipose tissues in vivo is NO dependent. Am J Physiol Endocrinol Metab 1998; 274:E692-E699.
60. ReungjuiS, Hu H,Mu W, et al..Thiazide-induced subtle renal injury not observed in states of equivalent hypokalemia. Kidney Int 2007; 72:1483-1492.
61. Yang BC, Li DY, Weng Y, et al. Increased superoxide anion generation and altered vasoreactivity in rabbits on low-potassium diet. Am J Physiol 1998; 274:1955-1961.
62. Nakagawa T, Hu H, Zharikov S, et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 2006; 290:F625-F631.
63. Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005; 67:1739-1742.
64. Reungjui S, Roncal CA, Mu W, et al. Thiazide diuretics exacerbate fructose-induced metabolic syndrome. J Am Soc Nephrol 2007; 18:2724-2731.
65. Semenkin AA, Zhivilova LA, Golevtsova ZSh, et al. Comparative assessment of hypotensive, metabolic, and endothelial effects of indapamide-retard and hydrochlorothiazide in patients with essential hypertension. Kardiologiia 2006; 46:35-39.
66. Semenkin AA. Possibilities of using indices of vascular wall function as markers of negative metabolic effects of treatment with thiazide diuretics in patients with essential hypertension. Ter Arkh 2007; 79:31-38.
67. Zhou MS, Schulman IH, Jaimes EA, Raij L. Thiazide diuretics, endothelial function, and vascular oxidative stress. J Hypertens 2008; 26:494-500.
68. Klingbeil AU, John S, Schneider MP, et al. Effect of AT1 receptor blockade on endothelial function in essential hypertension. Am J Hypertens 2003; 16:123-128.
69. Muiesan ML, Salvetti M, Monteduro C, et al. Effect of treatment on flow-dependent vasodilation of the brachial artery in essential hypertension. Hypertension 1999; 33:575-580.
70. Fletcher A, Amery A, Birkenhager W, et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. J Hypertens 1991; 9:225-230.
71. Voyaki SM, Staessen JA, Thijs L, et al. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. J Hypertens 2001; 19:511 -519.
72. Savage PJ, Pressel SL, Curb JD, et al. Influence of long-term low-dose diuretic-based antihypertensive therapy on glucose, lipid, uric acid and potassium levels in older men and women with isolated systolic hypertension. The Systolic Hypertension in the Elderly Program. Arch Intern Med 1999; 158:741 -751.
73. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356:366-372.
74. Hawkins RG, Houston MC. Is population-wide diuretic use directly associated with the incidence of end-stage renal disease in the United States? A hypothesis. Am J Hypertens 2005; 18:744-749.
75. Hawkins RG. Is population-wide diuretic use directly associated with the incidence of end-stage renal disease in the United States? Curr Hypertens Rep 2006; 8:219-225.
76. Loffing J, Loffing-Cueni D, Hegyi I, et al. Thiazide treatment of rats provokes apoptosis in distal tubule cells. Kidney Int 1996; 50:1180-1190.
77. Mazzali M, Kanellis J, Han L, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002; 282:F991-F997.
78. Nakagawa T, Mazzali M, Kang DH, et al. Uric acid-a uremic toxin? Blood Purif 2006; 24:67-70.
79. Kang DH, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002; 13:2888-2897.
80. Kang DH, Nakagawa T. Uric acid and chronic renal disease: possible implication of hyperuricemia on progression of renal disease. Semin Nephrol 2005; 25:43-49.
81. Iseki K, Ikemiya Y, Inoue T, et al. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 2004; 44:642- 650.
82. Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006; 47:51-59.